Arcutis Biotherapeutics (NASDAQ:ARQT) Downgraded by Mizuho
Mizuho cut shares of Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) from a buy rating to a neutral rating in a research report released on Thursday morning, MarketBeat.com reports. ARQT has been the subject of a number of other reports. TD Cowen lowered their price target on Arcutis Biotherapeutics from $65.00 to $50.00 and set an […]
More Stories
Columbia Sportswear (NASDAQ:COLM) Issues Q3 Earnings Guidance
Columbia Sportswear (NASDAQ:COLM – Get Free Report) issued an update on its third quarter earnings guidance on Thursday morning. The...
Boston Beer (NYSE:SAM) Announces Quarterly Earnings Results
Boston Beer (NYSE:SAM – Get Free Report) posted its quarterly earnings data on Thursday. The company reported $4.39 earnings per...
Bitcoin Gold Market Cap Tops $457.42 Million (BTG)
Bitcoin Gold (BTG) traded up 4.7% against the dollar during the 1-day period ending at 22:00 PM Eastern on July...
AbbVie (NYSE:ABBV) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS
AbbVie (NYSE:ABBV – Get Free Report) posted its earnings results on Thursday. The company reported $2.65 EPS for the quarter,...
Bluzelle (BLZ) Trading 8.7% Lower Over Last Week
Bluzelle (BLZ) traded up 1% against the U.S. dollar during the one day period ending at 22:00 PM E.T. on...
Bitcoin Diamond (BCD) Tops 24-Hour Volume of $4,433.51
Bitcoin Diamond (BCD) traded 10.4% higher against the dollar during the twenty-four hour period ending at 22:00 PM Eastern on...